Selling to biotech means navigating complex org charts where researchers influence, procurement controls budgets, and regulatory teams have veto power. Traditional prospecting treats them all the same and wastes months chasing the wrong contacts.
Biotechnology sales involves 12-24 month cycles, highly specialized buyers, and decisions made by committees of scientists, clinical teams, procurement, and executives. Generic prospecting tools can't tell a principal investigator from a lab manager - AI that understands the life sciences can.
Here's what's actually happening:
| Factor | Traditional Method | AI Method |
|---|---|---|
| Approach | Buy life sciences lists, blast emails to anyone with 'research' or 'scientist' in title, hope for responses | AI analyzes each biotech company's therapeutic focus, pipeline stage, recent publications, and team structure to identify the right scientists and procurement contacts. Outreach is tailored to their specific research challenges and therapeutic areas. |
| Time Required | 350-450 hours to build qualified pipeline of 40 opportunities | 90-120 hours to build same qualified pipeline |
| Cost | $25k-35k/month in SDR time and tools | $3,500-5,000/month with our service |
| Success Rate | 0.8-1.5% response rate on cold outreach | 9-14% response rate on targeted outreach |
| Accuracy | 40% of contacts are actually relevant decision-makers | 98% of contacts are verified relevant decision-makers |
83% of biotech purchasing decisions
Involve 6+ stakeholders across research, clinical operations, regulatory, procurement, and executive teams. AI mapping of org structures identifies the full buying committee before you even call.
BIO Industry Analysis 2024
Scientific buyers spend 71% of their evaluation time
Reading peer-reviewed studies, technical specifications, and validation data before engaging with sales. AI identifies which prospects have attended scientific conferences or published in relevant therapeutic areas.
Life Sciences Marketing Research Council
Average biotech sales cycle
Has increased from 14 months to 19 months since 2020 due to increased regulatory scrutiny and budget constraints. This makes every qualified meeting more valuable - wasting time on bad fits is catastrophic.
Evaluate Pharma Commercial Excellence Report 2024
Companies with AI-assisted prospecting in life sciences
Report 47% faster time-to-qualified-pipeline when targeting biotech buyers. The key is AI understanding therapeutic areas, pipeline stages, and scientific buyer personas, not just company demographics.
Industry benchmarks suggest
AI analyzes each biotech company's therapeutic focus, pipeline stage, recent publications, and team structure to identify the right scientists and procurement contacts. Outreach is tailored to their specific research challenges and therapeutic areas.
The key difference: AI doesn't replace the human element - it handles the low-value research work so experienced reps can focus on high-value strategic calls.
AI reads each company's pipeline, publications, and clinical trial registrations to understand their therapeutic focus - oncology, immunology, rare diseases, gene therapy, etc. This determines which of your solutions are relevant. An antibody discovery company has different needs than a cell therapy manufacturer.
A company in preclinical research has different purchasing priorities than one preparing for Phase III trials. AI tracks funding rounds, clinical trial progression, and regulatory milestones to identify companies whose stage aligns with your offering and who have budget to spend.
Biotech decisions involve principal investigators, research directors, lab managers, clinical operations, and regulatory affairs. AI maps the org chart to identify who influences vs who decides. The VP of Research often defers to the Principal Scientist on technical decisions.
Job postings reveal research direction and growth. A company hiring 8 process development scientists is scaling toward manufacturing. One hiring bioinformaticians is investing in computational biology. AI identifies companies whose research roadmap aligns with your solution.
Scientists who publish in Nature, present at AACR, or speak at therapeutic area conferences are thought leaders in their organizations. AI identifies these individuals as high-value contacts who influence purchasing decisions and understand cutting-edge solutions.
What instruments, software, and services does the target company already use? AI identifies this from job postings, publications, and press releases. Companies using complementary technologies may be ideal prospects. Those using competitor solutions may be ripe for switching.
Biotech sales is scientific and complex. Generic prospecting tools fail because they don't understand therapeutic areas, pipeline stages, or how scientific organizations make decisions. Use these questions to evaluate any solution.
In biotech, a 'Research Director' in oncology has completely different needs than one in gene therapy. Can the tool identify therapeutic specialization beyond job title? Can it tell a discovery scientist from a process development scientist, and understand why that matters for your solution?
Biotech purchases often align with pipeline milestones, funding events, and regulatory submissions - not calendar quarters. Can the tool identify where companies are in their development cycle? A company preparing for IND filing has different urgency than one in early discovery.
Biotech buyers reveal intent through scientific activity - publications, conference presentations, clinical trial registrations, patent filings. Can the tool track these signals, or does it only know company size and funding?
Biotech deals require engaging research teams, clinical operations, regulatory affairs, procurement, and executives simultaneously. Can the tool identify the full buying committee across these diverse functions and track engagement across all stakeholders?
Generic B2B databases miss biotech-specific signals. Does the tool integrate with ClinicalTrials.gov, PubMed, patent databases, scientific conference records, FDA filings, or therapeutic area publications? These sources reveal true buying intent.
Their SDR team was cold-calling biotech companies from generic life sciences lists. They had no way to tell which scientists actually made purchasing decisions or what therapeutic areas each company focused on. Half their meetings were with lab managers who 'needed to check with the research director' or scientists in the wrong therapeutic area. Even worse, their generic outreach about 'accelerating research' fell flat with scientific buyers who wanted to see validation data and peer-reviewed evidence.
With AI-powered targeting, every call now goes to a verified decision-maker whose therapeutic area and pipeline stage match their solution. Pre-call briefings include the prospect's recent publications, their company's clinical pipeline, and specific pain points based on their research focus. Response rates jumped from 1.2% to 12%, but more importantly, meeting-to-opportunity conversion hit 52% because they're finally talking to scientists who can actually buy and whose research needs align perfectly.
Week 1: AI analyzed 650 target biotech companies, identifying 1,800 relevant contacts across research, clinical operations, and leadership based on therapeutic area alignment
Week 2: Each contact was scored based on scientific influence, purchasing authority, pipeline stage, and recent funding - 280 were flagged as high-priority based on therapeutic fit
Week 3: First outreach campaign launched with scientific messaging tailored to each prospect's specific therapeutic area, pipeline stage, and published research
Week 4: 12% response rate vs 1.2% historical - scientific buyers responded because outreach demonstrated deep understanding of their research challenges
Month 2: First deals entering pipeline with average 45% shorter time-to-qualified-opportunity and 3x higher deal sizes
We've built our AI system specifically to understand life sciences and biotechnology. Our team includes former biotech sales professionals who know the difference between a principal investigator and a lab manager, understand therapeutic areas, and know why pipeline stage matters for purchasing decisions.
Working with Fortune 500 distributors and semiconductor companies. Same system, your prospects.
Get Started →Stop wasting time on biotech companies that will never buy. Here's how AI ensures you only call perfect-fit prospects in the biotechnology and life sciences market.
AI works with any data source - CRM export, wish list, or just target therapeutic areas and pipeline stages. Even if you just have company names or a rough idea of which biotech segments you want to reach.
AI researches each biotech company against YOUR specific criteria: therapeutic area alignment, pipeline stage, funding status, team size, research focus, technology platform, and any custom qualification rules you need for your solution.
From 2,500 biotech companies, AI might qualify just 280 that are perfect fits. No more wasted calls to companies in the wrong therapeutic area, wrong pipeline stage, or without budget.
The biggest challenge isn't finding biotech companies - it's finding the RIGHT SCIENTIST who has influence AND purchasing authority AND is reachable.
Chief Scientific Officer: Perfect authority, but no direct contact info and too senior for initial outreach
Principal Investigator: Right scientific expertise and influence, but just moved from academia last month
Lab Manager: Has contact info, but no purchasing authority for your solution
VP of Research: Budget authority + scientific credibility + verified phone number = Perfect!
AI identifies all potential contacts across research, clinical operations, regulatory affairs, procurement, and leadership at each biotech company, understanding the unique structure of scientific organizations
Checks who actually has working phone numbers and valid email addresses right now, and validates their therapeutic area expertise matches your solution
Finds the highest-authority person with relevant scientific expertise who ALSO has verified contact information and is appropriate for initial outreach
Builds talking points specific to that person's research focus, their therapeutic area challenges, recent publications, and pipeline priorities
Never stumble for what to say to biotech buyers. AI analyzes publications, clinical trials, and research focus to prepare personalized talking points that resonate with scientific decision-makers.
"I noticed Nexus just published promising Phase I data for your CAR-T program in Blood Cancer Journal - congratulations on those results. Most cell therapy leaders tell me that scaling manufacturing while maintaining quality is their biggest challenge as they move toward Phase II..."
"With your pipeline advancing to later stages, you're likely dealing with significant process development challenges. Companies at your stage typically see 40% of research time lost to manual processes that could be automated..."
"Your recent job postings for process development scientists suggest you're scaling manufacturing capabilities. Are your teams spending more time on documentation and compliance than actual research? That's exactly what the VP of Research at CellGen told me before we started working together..."
"Three other CAR-T companies - ImmunoCell, TherapyGen, and OncoVax - are already using our platform to streamline their process development. ImmunoCell reduced their IND prep time by 5 months in their second program..."
AI prepares custom research and biotech-specific talking points including therapeutic area context, pipeline analysis, and scientific publications for 80+ calls daily
With all the preparation complete, AI makes every call count and ensures no biotech opportunity falls through the cracks during long sales cycles.
AI-optimized call lists with auto-dialers maximize efficiency. Every dial is to a pre-qualified, researched biotech prospect in the right therapeutic area and pipeline stage.
Every call uses AI-prepared talking points with therapeutic area-specific terminology and scientific context. Reps know exactly what to say to engage research directors and scientific buyers.
Every call is logged, recorded, and tracked with therapeutic area tags and pipeline stage notes. AI captures insights and updates CRM automatically with scientific context.
Never miss another biotech opportunity during long sales cycles. AI ensures every prospect gets perfectly timed touches with relevant scientific content until they're ready to buy.
AI automatically sends personalized email with relevant scientific content based on the therapeutic area-specific conversation
"Hi Dr. Chen, loved your point about needing to streamline process development for your CAR-T program. Here's how we helped ImmunoCell reduce IND prep time by 5 months..."
AI sends relevant case study or white paper based on their specific therapeutic area and pipeline stage
"Dr. Chen, thought you'd find this relevant - how CellGen scaled their cell therapy manufacturing while maintaining compliance [validation data included]"
Prospect automatically appears at top of call list with updated talking points based on any new publications, clinical trial updates, or funding announcements
Continues with 15+ perfectly timed touches aligned with their pipeline milestones until they're ready to meet
Every biotech prospect stays warm with automated multi-channel nurturing that includes relevant scientific content, therapeutic area insights, and pipeline-stage-appropriate messaging. AI ensures perfect timing and scientific relevance at scale throughout long biotech sales cycles.
We've spent years perfecting the AI-powered prospecting system. Our dedicated team runs it for you - handling everything from qualification to booked meetings. You just show up and close.
We built the perfect AI-driven prospecting system. Now our dedicated team runs it for you.
Our AI analyzes thousands of companies to find only those that match your ICP - before we ever pick up the phone.
Recent news, trigger events, pain points, tech stack - we know everything before making contact.
Our trained team handles all outreach - email, LinkedIn, and phone - using proven scripts and perfect timing.
Qualified prospects are scheduled directly on your calendar. You just show up and close.
Full reporting on activity, response rates, and pipeline generation - complete transparency.
Every week we refine messaging, improve targeting, and increase conversion rates.
See why outsourcing prospecting delivers better results at lower cost
Your team with random prospecting
200 conversations/month
Our strategic approach
3,000 conversations/month
2,800 more quality conversations per month
The math is simple when you break it down
Your Closers Close
Stop asking expensive AEs to prospect. Let them do what they do best while we fill their calendars.
Tell us about your sales goals. We'll show you how to achieve them with our proven system.